ZEB1 hypermethylation is associated with better prognosis in patients with colon cancer
2023
Fernández García, V. | Calvo, L. | Suárez Seoane, Susana | Marcos, E.
Colon cancer (CC) is a heterogeneous disease that is categorized into four Consensus Molecular Subtypes (CMS) according to gene expression. Patients with loco-regional CC (stages II/III) lack prognostic factors, making it essential to analyze new molecular markers that can delineate more aggressive tumors. Aberrant methylation of genes that are essential in crucial mechanisms such as epithelial mesenchymal transition (EMT) contributes to tumor progression in CC. We evaluate the presence of hyper- and hypomethylation in subrogate IHC markers used for CMS classification (CDX2, FRMD6, HTR2B, ZEB1) of 144 stage II/III patients and CC cell lines by pyrosequencing. ZEB1 expression was also studied in control and shRNA-silenced CC cell lines and in paired normal tissue/tumors by quantitative PCR. The pattern of ZEB1 staining was also analyzed in methylated/unmethylated tumors by immunohistochemistry.
Show more [+] Less [-]This research was funded by European Union Regional Development Fund (17–20, RefBioII, Trans‑Pyrenean cooperation network program 2016–2018, INTERREG‑ POCTEFA)
Show more [+] Less [-]Bibliographic information
This bibliographic record has been provided by Universidad de Oviedo
